Lynn Frazier
Acute Care · Little Rock, ARNPI 1619918505
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,214 of the $106,239 with a category attached, or 60.4%. 28 manufacturers reported payments, led by Gilead at 45.7% of the total. 2025 is the largest year on record at $31,775, 2.5 times the $12,795 reported in 2021. Among acute care clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 515 payments — averaging $206.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$49K
- Intercept Pharmaceuticals, Inc.$20K
- Ipsen Biopharmaceuticals, Inc$15K
- Madrigal Pharmaceuticals$13K
- AbbVie$5K
- Janssen Scientific Affairs, LLC$1K
- plus $2K from 22 others
What the payments were for
- Consulting fees$2,8703%
- Speaking & faculty fees$64,21460%
- Travel & lodging$26,41425%
- Food & beverage$12,74212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 154 | $48,534 |
| Intercept Pharmaceuticals, Inc. | 69 | $20,449 |
| Ipsen Biopharmaceuticals, Inc | 31 | $15,188 |
| Madrigal Pharmaceuticals | 43 | $13,143 |
| AbbVie(2 entities) | 109 | $5,347 |
| Janssen Scientific Affairs, LLC | 13 | $1,113 |
| Viiv Healthcare Company | 31 | $680 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $541 |
| Johnson & Johnson(2 entities) | 6 | $335 |
| Novo Nordisk | 6 | $163 |
| Mirum Pharmaceuticals, Inc. | 1 | $150 |
| Redhill Biopharma Inc. | 7 | $130 |
| Axsome Therapeutics, Inc. | 1 | $104 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Evoke Pharma, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Merck | 1 | $28 |
| Shield Therapeutics Inc | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Medtronic | 1 | $18 |
| Pfizer | 1 | $16 |
| Genentech USA, Inc. | 2 | $15 |
| Bayer | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,239 in reported general payments places this provider in the 95th percentile of 321 acute care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 59 | $1,366,269 |
| XifaxanRifaximin | 215 | $694,076 |
| RezdiffraResmetirom | 63 | $246,972 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $236,774 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 55 | $222,192 |
| OcalivaObeticholic Acid | 27 | $221,021 |
| MavyretGlecaprevir/Pibrentasvir | 11 | $143,927 |
| VemlidyTenofovir Alafenamide | 44 | $69,237 |
| Ursodiol | 149 | $20,655 |
| LinzessLinaclotide | 19 | $11,576 |
| Entecavir | 23 | $10,943 |
| Tenofovir Disoproxil Fumarate | 64 | $7,556 |
| Lactulose | 136 | $4,202 |
| Dexlansoprazole DrDexlansoprazole | 12 | $3,650 |
| Omeprazole | 139 | $3,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Biktarvy, Vemlidy | $48,534 | $1,657,698158 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $541 | $694,076215 claims |
| Madrigal PharmaceuticalsRezdiffra | $13,143 | $246,97263 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $20,449 | $221,02127 claims |
| AbbVieMavyret, Linzess | $5,347 | $155,50330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 acute care providers in Arkansas.
Other acute care in Little Rock
- Jill AveryLittle Rock$117K
- Beverly BaxterLittle Rock$95K
- Diane GlendinningLittle Rock$26K
- Beth CrowderLittle Rock$25K
- Carmen Paniagua TorresLittle Rock$21K
- Shana KloskeLittle Rock$14K
- Debra BrentLittle Rock$9K
- Ginger HartLittle Rock$9K
- Holly TrottaLittle Rock$7K
- Katelyn LomaxLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.